Mercer Global Advisors
TRVI icon

Mercer Global Advisors’s Trevi Therapeutics TRVI Stock Holding History

Mercer Global Advisors’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.4K Buy
+2,221
New +$32.3K ﹤0.01% 4415

Other funds holding TRVI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Mercer Global Advisors's TRVI Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Trevi Therapeutics (TRVI) in Q2 2026: 2,221 shares worth $41.4K. The stake represents ﹤0.01% of the portfolio and ranks #4415 among its holdings.

196 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Mercer Global Advisors held 2,221 shares of Trevi Therapeutics worth $41.4K as of Q2 2026.
  • Trevi Therapeutics was a new Mercer Global Advisors position in Q2 2026.
  • Trevi Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #4415 holding.
  • 196 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.